| 周元,许邦龙,高峰.心房颤动合并冠心病冠状动脉介入治疗术后达比加群酯抗凝治疗的有效性及安全性研究[J].安徽医药,2019,23(4):657-660. |
| 心房颤动合并冠心病冠状动脉介入治疗术后达比加群酯抗凝治疗的有效性及安全性研究 |
| Efficacy and safety of dabigatran etexilate in anticoagulant therapy after PCI operation of patients with atrial fibrillation and coronary heart disease |
| 投稿时间：2017-11-01 |
| DOI： |
| 中文关键词: 心房颤动 冠心病 达比加群酯 华法林 血管成形术,气囊,冠状动脉 |
| 英文关键词: Coronary disease Atrial fibrillation Dabigatran etexilate Warfarin Angioplasty,balloon,coronary |
| 基金项目: |
|
| 摘要点击次数: 2082 |
| 全文下载次数: 627 |
| 中文摘要: |
| 目的 研究达比加群酯(dabigatran etexilate)在心房颤动(房颤)合并冠心病冠状动脉介入治疗(PCI)术后抗凝治疗中的有效性及安全性。方法 选取2015年3月至2016年3月安徽医科大学第二附属医院收治的房颤合并冠心病冠状动脉介入治疗病人90例,采用随机数字表法分为观察组和对照组,每组45例。观察组每天两次口服达比加群酯110 mg；对照组予以华法林治疗,调节国际标准化比值(INR)至2.0~3.0之间；同时两组均予以阿司匹林100 mg/d。观察随访12个月,比较两组病人实验室指标变化、新发急性心肌梗死、急性脑梗死、非中枢神经系统栓塞、出血事件及不良反应的发生率。结果 观察组中栓塞事件发生率(8.9%)与对照组(17.8%)相比差异无统计学意义(χ2=1.538,P=0.215)；达比加群酯在降低与血栓形成有关的实验室指标上较华法林更优,同时观察组出血事件发生率低于对照组(χ2=4.406,P=0.036)；两组在不良反应事件发生率上均差异无统计学意义(P>0.05)。结论 达比加群酯在房颤合并冠心病PCI术后病人抗凝治疗中与华法林的疗效相似,且达比加群酯的安全性更高,是此类病人抗凝治疗的理想选择。 |
| 英文摘要: |
| Objective To explore the effectiveness and safety of using dabigatran etexilate during anticoagulant therapy after percutaneous coronary intervention (PCI) operation of atrial fibrillation and coronary heart disease.Methods Ninety cases of patients in the Second Affiliated Hospital of Anhui Medical University from March 2015 to March 2016 were selected and assigned into observation group and control group by random number table method,with 45 patients in each group.The observation group took orally 110 mg eabigatran etexilate twice a day,while the control group was treated with Warfarin,international normalized ratio (INR) adjusted within 2.0-3.0.In the meantime,both groupstook 100 mg aspirin every day.Patients were followed up for 12 months,and comparison was made of the laboratory index change,and the occurrence rates of new onset of acute myocardial infarction,acute cerebral infarction,embolism in non-central nervous system,bleeding events and other adverse reactions between two groups.Results There was no statistical significance in the incidence of embolism in observation group (8.9%) compared with control group (17.8%) (χ2=1.538,P=0.215).Dabigatran etexilate was superior to arfarin in reducing laboratory indicators related to thrombosis,meanwhile,the occurrence rate of bleeding events in observation group was lower than that in control group (χ2=4.406,P=0.036);there was no significant difference in the occurrence rate of adverse reactions (P>0.05).Conclusion Dabigatran etexilate is similar to Warfarin in anticoagulant therapy after PCI operation of patients with atrial fibrillation and coronary heart disease,and dabigatran etexilate is safer and is an ideal choice for anticoagulant therapy in such patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
